Impact of genetic abnormalities on survival after allogeneic hematopoietic stem cell transplantation in multiple myeloma. (Q46640315)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18418408%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

title

Impact of genetic abnormalities on survival after allogeneic hematopoietic stem cell transplantation in multiple myeloma (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18418408%20AND%20SRC:MED&resulttype=core&format=json

Erratum: Impact of genetic abnormalities on survival after allogeneic hematopoietic stem cell transplantation in multiple myeloma

5 January 2020

corrigendum / erratum

0 references

author

Norma C. Gutiérrez

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18418408%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

Jesús San Miguel

19

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18418408%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

10

M Bornhäuser

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18418408%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

author name string

G Schilling

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18418408%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

T Hansen

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18418408%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

A Shimoni

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18418408%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

T Zabelina

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18418408%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

J-A Pérez-Simón

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18418408%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

W Bethge

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18418408%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

P Liebisch

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18418408%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

R Schwerdtfeger

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18418408%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

S Otterstetter

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18418408%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

E M M Penas

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18418408%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

J Dierlamm

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18418408%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

F Ayuk

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18418408%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

D Atanackovic

15

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18418408%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

U Bacher

16

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18418408%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

C Bokemeyer

17

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18418408%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

A Zander

18

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18418408%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

A Nagler

20

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18418408%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

N Kröger

21

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18418408%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

publication date

17 April 2008

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18418408%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18418408%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

volume

22

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18418408%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

issue

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18418408%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

page(s)

1250-1255

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18418408%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1038/leu.2008.88

5 January 2020

exact match

0 references

cites work

Prognostic impact of cytogenetic and interphase fluorescence in situ hybridization-defined chromosome 13 deletion in multiple myeloma: early results of total therapy II.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.88

7 January 2021

Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myélome.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.88

7 January 2021

Oncogenesis of multiple myeloma: 14q32 and 13q chromosomal abnormalities are not randomly distributed, but correlate with natural history, immunological features, and clinical presentation

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.88

7 January 2021

Rearrangements of the c-myc oncogene are present in 15% of primary human multiple myeloma tumors

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.88

7 January 2021

p53 gene deletion detected by fluorescence in situ hybridization is an adverse prognostic factor for patients with multiple myeloma following autologous stem cell transplantation

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.88

7 January 2021

The t(4;14) is associated with poor prognosis in myeloma patients undergoing autologous stem cell transplant

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.88

7 January 2021

Chromosome 13 abnormalities identified by FISH analysis and serum beta2-microglobulin produce a powerful myeloma staging system for patients receiving high-dose therapy

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.88

7 January 2021

Clinical and biologic implications of recurrent genomic aberrations in myeloma

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.88

7 January 2021

Clinical implications of t(11;14)(q13;q32), t(4;14)(p16.3;q32), and -17p13 in myeloma patients treated with high-dose therapy

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.88

7 January 2021

Prognostic and biological implications of genetic abnormalities in multiple myeloma undergoing autologous stem cell transplantation: t(4;14) is the most relevant adverse prognostic factor, whereas RB deletion as a unique abnormality is not associated

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.88

7 January 2021

Recurrent 14q32 translocations determine the prognosis of multiple myeloma, especially in patients receiving intensive chemotherapy

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.88

7 January 2021

Prognostic and therapeutic significance of myeloma genetics and gene expression profiling.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.88

7 January 2021

Deletion of chromosome band 13q14 as detected by fluorescence in situ hybridization is a prognostic factor in patients with multiple myeloma who are receiving allogeneic dose-reduced stem cell transplantation

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.88

7 January 2021

Autologous stem cell transplantation followed by a dose-reduced allograft induces high complete remission rate in multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.88

7 January 2021

Improved outcome of allogeneic transplantation in high-risk multiple myeloma patients after nonmyeloablative conditioning

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.88

7 January 2021

A comparison of allografting with autografting for newly diagnosed myeloma

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.88

7 January 2021

Allografting with nonmyeloablative conditioning following cytoreductive autografts for the treatment of patients with multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.88

7 January 2021

Prospective comparison of autologous stem cell transplantation followed by dose-reduced allograft (IFM99-03 trial) with tandem autologous stem cell transplantation (IFM99-04 trial) in high-risk de novo multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.88

7 January 2021

Reduced-intensity conditioning allogeneic transplantation is associated with a high incidence of extramedullary relapses in multiple myeloma patients

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.88

7 January 2021

Determination of chromosome 13 status in bone marrow cells of patients with multiple myeloma using combined morphologic and fluorescence in situ hybridization analysis

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.88

7 January 2021

Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.88

7 January 2021

Relapse to prior autograft and chronic graft-versus-host disease are the strongest prognostic factors for outcome of melphalan/fludarabine-based dose-reduced allogeneic stem cell transplantation in patients with multiple myeloma.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.88

7 January 2021

Frequent translocation t(4;14)(p16.3;q32.3) in multiple myeloma is associated with increased expression and activating mutations of fibroblast growth factor receptor 3

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.88

7 January 2021

A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.88

7 January 2021

Heterogeneity of t(4;14) in multiple myeloma. Long-term follow-up of 100 cases treated with tandem transplantation in IFM99 trials

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.88

7 January 2021